Cerus Corp. (NASDAQ:CERS) was down 2.2% during trading on Thursday . The stock traded as low as $6.23 and last traded at $6.26, with a volume of 478,327 shares. The stock had previously closed at $6.40.

Several research analysts recently issued reports on CERS shares. BTIG Research reissued a “buy” rating and set a $10.00 target price (up previously from $8.00) on shares of Cerus Corp. in a report on Friday, April 22nd. Cantor Fitzgerald reissued a “buy” rating and set a $9.00 target price on shares of Cerus Corp. in a report on Thursday. Robert W. Baird reissued an “outperform” rating and set a $9.00 target price on shares of Cerus Corp. in a report on Wednesday, June 22nd. Finally, FBR & Co reissued a “buy” rating on shares of Cerus Corp. in a report on Wednesday, May 4th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Cerus Corp. has an average rating of “Buy” and an average price target of $8.90.

The firm’s 50-day moving average price is $5.92 and its 200-day moving average price is $5.80. The stock’s market capitalization is $656.03 million.

Cerus Corp. (NASDAQ:CERS) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.01. The business had revenue of $7.60 million for the quarter, compared to the consensus estimate of $8.29 million. The company’s revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.17) earnings per share. Equities analysts expect that Cerus Corp. will post ($0.65) EPS for the current fiscal year.

Several hedge funds and institutional investors recently modified their holdings of the stock. California State Teachers Retirement System boosted its position in shares of Cerus Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 176,709 shares of the company’s stock valued at $1,117,000 after buying an additional 3,126 shares during the last quarter. Stephens Inc. AR boosted its position in shares of Cerus Corp. by 11.3% in the fourth quarter. Stephens Inc. AR now owns 1,112,665 shares of the company’s stock valued at $7,032,000 after buying an additional 113,238 shares during the last quarter. Rail Splitter Capital Management LLC boosted its position in shares of Cerus Corp. by 19.0% in the fourth quarter. Rail Splitter Capital Management LLC now owns 832,722 shares of the company’s stock valued at $5,263,000 after buying an additional 132,970 shares during the last quarter. EAM Investors LLC bought a new position in shares of Cerus Corp. during the fourth quarter valued at about $1,139,000. Finally, Wells Fargo & Company MN boosted its position in shares of Cerus Corp. by 25.9% in the fourth quarter. Wells Fargo & Company MN now owns 4,901,666 shares of the company’s stock valued at $30,979,000 after buying an additional 1,007,430 shares during the last quarter.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.